Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Eder

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
High-dose ifosfamide with mesna uroprotection: a phase I studyA D Elias, J P Eder, T Shea, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant sublineJ P Eder, B A Teicher, S A Holden, et al.
Cancer Research|November 1, 1989
Influence of schedule on alkylating agent cytotoxicity in vitro and in vivoB A Teicher, S A Holden, J P Eder, et al.
Cancer Research|February 1, 1989
Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agentsJ P Eder, B A Teicher, S A Holden, et al.
Seminars in Oncology|February 1, 1990
Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combinationB A Teicher, S A Holden, J P Eder, et al.
Clinical Science (London, England : 1979)|November 1, 1989
Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantationS W Graves, J P Eder, S M Schryber, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamineG N Schwartz, B A Teicher, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|September 23, 1998
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivoJ P Eder, V Chan, J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusionJ P Eder, J G Supko, T Lynch, et al.
Cancer Research|September 1, 1986
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapyJ P Eder, R C Bast, W P Peters, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
High-dose ifosfamide with mesna uroprotection: a phase I studyA D Elias, J P Eder, T Shea, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant sublineJ P Eder, B A Teicher, S A Holden, et al.
Cancer Research|November 1, 1989
Influence of schedule on alkylating agent cytotoxicity in vitro and in vivoB A Teicher, S A Holden, J P Eder, et al.
Cancer Research|February 1, 1989
Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agentsJ P Eder, B A Teicher, S A Holden, et al.
Seminars in Oncology|February 1, 1990
Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combinationB A Teicher, S A Holden, J P Eder, et al.
Clinical Science (London, England : 1979)|November 1, 1989
Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantationS W Graves, J P Eder, S M Schryber, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamineG N Schwartz, B A Teicher, J P Eder, et al.
Cancer Chemotherapy and Pharmacology|September 23, 1998
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivoJ P Eder, V Chan, J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusionJ P Eder, J G Supko, T Lynch, et al.
Cancer Research|September 1, 1986
Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapyJ P Eder, R C Bast, W P Peters, et al.
Pageof 6